Heart failure & cardiomyopathies
Medicines Optimization Prior to Discharge in Patients Admitted to Hospital with Heart Failure
Authors' conclusion
Most patients admitted for heart failure are eligible for initiation of life-prolonging medications prior to discharge.
Study context
- Population
- Patients admitted to hospital with suspected HF, Kingston upon Hull, UK, 2012–2017; Heart failure and a reduced ejection fraction (HeFREF) analysed455 HeFREF analysed
- Participants
- 1,277 patients
- Outcome
- Proportion on optimal doses prior to discharge and proportion eligible for initiation of sacubitril-valsartan or SGLT2 inhibitors
- Follow-up
- Prior to discharge
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
discharge
- Taking ACEi or ARB at discharge
- 83%
- Taking beta-blocker at discharge
- 85%
- Taking MRA at discharge
- 63%
- Eligible for sacubitril-valsartan
- >60%
- Eligible for SGLT2 inhibitor
- >70%
- Not already prescribed, eligible to start ACEi or ARB
- 37%
- Not already prescribed, eligible to start beta-blocker
- 28%
- Not already prescribed, eligible to start MRA
- 49%
Observational data: associations, not effects.
Further findings
Reason for failure to initiate or up-titrate therapy
- Low systolic blood pressure (SBP) (≤105 mmHg) the most frequent explanation
Original publication
Medicines Optimization Prior to Discharge in Patients Admitted to Hospital with Heart Failure. ESC Heart Fail. Published 16 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →